Summary
5.41 -0.12(-2.17%)09/06/2024
uniQure N.V. (QURE)
uniQure N.V. (QURE)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| -1.46 | -7.52 | -28.72 | 1.98 | 4.24 | -31.17 | -87.84 | -62.97 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 5.41 | |
| Open | 5.53 | |
| High | 5.56 | |
| Low | 5.28 | |
| Volume | 277,140 | |
| Change | -0.08 | |
| Change % | -1.46 | |
| Avg Volume (20 Days) | 380,318 | |
| Volume/Avg Volume (20 Days) Ratio | 0.73 | |
| 52 Week Range | 3.73 - 11.35 | |
| Price vs 52 Week High | -52.33% | |
| Price vs 52 Week Low | 45.04% | |
| Range | -2.17 | |
| Gap Up/Down | -0.06 | |
Fundamentals | ||
| Market Capitalization (Mln) | 264 | |
| EBIDTA | -255,076,000 | |
| PE Ratio | 0.0000 | |
| PEG Ratio | 0.0000 | |
| WallStreet Target Price | 19.92 | |
| Book Value | 4.3410 | |
| Earnings Per Share | -6.4700 | |
| EPS Estimate Current Quarter | -1.2800 | |
| EPS Estimate Next Quarter | -1.2400 | |
| EPS Estimate Current Year | -4.5300 | |
| EPS Estimate Next Year | -3.8300 | |
| Diluted EPS (TTM) | -6.4700 | |
| Revenues | ||
| Profit Marging | 0.0000 | |
| Operating Marging (TTM) | -9.1634 | |
| Return on asset (TTM) | -0.2172 | |
| Return on equity (TTM) | -0.9024 | |
| Revenue TTM | 15,843,000 | |
| Revenue per share TTM | 0.3320 | |
| Quarterly Revenue Growth (YOY) | -0.9350 | |
| Quarterly Earnings Growth (YOY) | -0.1820 | |
| Gross Profit (TTM) | -87,370,000 | |
| Dividends | ||
| Dividend Share | 0.0000 | |
| Dividend Yield | ||
| Valuations | ||
| Trailing PE | 0.0000 | |
| Forward PE | 27.9330 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 1.1034 | |
| Revenue Enterprise Value | 13.0150 | |
| EBITDA Enterprise Value | 0.9891 | |
| Shares | ||
| Shares Outstanding | 48,549,400 | |
| Shares Float | 37,841,989 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.05 | |
| Insider (%) | 4.35 | |
| Institutions (%) | 82.52 | |
08/15 07:05 EST - globenewswire.com
uniQure Announces Dosing of First Patient in Phase I/IIa Clinical Trial of AMT-191 for the Treatment of Fabry Disease
LEXINGTON, Mass. and AMSTERDAM, Aug. 15, 2024 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that the first patient has been dosed in a Phase I/IIa clinical trial of AMT-191 for the treatment of Fabry disease, a rare, inherited genetic disease. The Phase I/IIa study is a multi-center, open-label trial being conducted in the United States with two dose-escalating cohorts assessing the safety, tolerability and early signs of efficacy of AMT-191 in individuals with Fabry disease.
uniQure Announces Dosing of First Patient in Phase I/IIa Clinical Trial of AMT-191 for the Treatment of Fabry Disease
LEXINGTON, Mass. and AMSTERDAM, Aug. 15, 2024 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that the first patient has been dosed in a Phase I/IIa clinical trial of AMT-191 for the treatment of Fabry disease, a rare, inherited genetic disease. The Phase I/IIa study is a multi-center, open-label trial being conducted in the United States with two dose-escalating cohorts assessing the safety, tolerability and early signs of efficacy of AMT-191 in individuals with Fabry disease.
08/06 03:03 EST - seekingalpha.com
uniQure: Pullback After Strong Interim Treatment Data Creates Buying Opportunity
uniQure N.V. released positive 24-month trial data for AMT-130 gene therapy for Huntington's Disease, leading to a significant stock price increase. The company has aggressively restructured to extend its cash runway, focusing on AMT-130 development with confidence in its success. Despite risks, including potential negative trial data, its strong balance sheet and upcoming catalysts make it possible for QURE stock to reach $15 by year-end.
uniQure: Pullback After Strong Interim Treatment Data Creates Buying Opportunity
uniQure N.V. released positive 24-month trial data for AMT-130 gene therapy for Huntington's Disease, leading to a significant stock price increase. The company has aggressively restructured to extend its cash runway, focusing on AMT-130 development with confidence in its success. Despite risks, including potential negative trial data, its strong balance sheet and upcoming catalysts make it possible for QURE stock to reach $15 by year-end.
08/01 09:25 EST - zacks.com
UniQure (QURE) Reports Q2 Loss, Tops Revenue Estimates
UniQure (QURE) came out with a quarterly loss of $1.16 per share versus the Zacks Consensus Estimate of a loss of $1.24. This compares to loss of $1.44 per share a year ago.
UniQure (QURE) Reports Q2 Loss, Tops Revenue Estimates
UniQure (QURE) came out with a quarterly loss of $1.16 per share versus the Zacks Consensus Estimate of a loss of $1.24. This compares to loss of $1.44 per share a year ago.
08/01 07:05 EST - globenewswire.com
uniQure Announces Second Quarter 2024 Financial Results and Provides Company Update
~ Announced RMAT designation for AMT-130 in Huntington's disease and positive interim Phase I/II data demonstrating the slowing of disease progression and reductions in a key biomarker of neurodegeneration; Meeting with FDA expected in the second half of 2024 to discuss potential for expedited clinical development ~
uniQure Announces Second Quarter 2024 Financial Results and Provides Company Update
~ Announced RMAT designation for AMT-130 in Huntington's disease and positive interim Phase I/II data demonstrating the slowing of disease progression and reductions in a key biomarker of neurodegeneration; Meeting with FDA expected in the second half of 2024 to discuss potential for expedited clinical development ~
07/26 10:55 EST - zacks.com
Wall Street Analysts See a 125.9% Upside in uniQure (QURE): Can the Stock Really Move This High?
The consensus price target hints at a 125.9% upside potential for uniQure (QURE). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Wall Street Analysts See a 125.9% Upside in uniQure (QURE): Can the Stock Really Move This High?
The consensus price target hints at a 125.9% upside potential for uniQure (QURE). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
07/23 07:05 EST - globenewswire.com
uniQure Announces Closing of Sale of Manufacturing Facility to Genezen
~ uniQure maintains preferential access to industry-leading manufacturing capabilities to support its pipeline of gene therapy candidates ~
uniQure Announces Closing of Sale of Manufacturing Facility to Genezen
~ uniQure maintains preferential access to industry-leading manufacturing capabilities to support its pipeline of gene therapy candidates ~
07/12 08:00 EST - forbes.com
What Led To A 150% Rise In UniQure Stock In A Week?
uniQure stock (NASDAQ: QURE), a gene therapy company, has seen a stellar 150% rise in a week, faring significantly better than its peer – Editas Medicine stock –, up 12%. This massive rise in QURE stock can be attributed to the positive outcome from its phase I-II clinical trials of AMT-130 for Huntington's disease.
What Led To A 150% Rise In UniQure Stock In A Week?
uniQure stock (NASDAQ: QURE), a gene therapy company, has seen a stellar 150% rise in a week, faring significantly better than its peer – Editas Medicine stock –, up 12%. This massive rise in QURE stock can be attributed to the positive outcome from its phase I-II clinical trials of AMT-130 for Huntington's disease.
07/10 10:55 EST - zacks.com
Wall Street Analysts Think uniQure (QURE) Could Surge 195.8%: Read This Before Placing a Bet
The consensus price target hints at a 195.8% upside potential for uniQure (QURE). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Wall Street Analysts Think uniQure (QURE) Could Surge 195.8%: Read This Before Placing a Bet
The consensus price target hints at a 195.8% upside potential for uniQure (QURE). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
07/10 10:06 EST - zacks.com
uniQure (QURE) Soars on New Huntington's Disease Study Data
uniQure (QURE) surges 77% on updated positive interim data from 29 treated patients in the ongoing phase I/II studies of investigational gene therapy, AMT-130, for Huntington's disease.
uniQure (QURE) Soars on New Huntington's Disease Study Data
uniQure (QURE) surges 77% on updated positive interim data from 29 treated patients in the ongoing phase I/II studies of investigational gene therapy, AMT-130, for Huntington's disease.
07/10 06:50 EST - zacks.com
uniQure (QURE) Surges 76.5%: Is This an Indication of Further Gains?
uniQure (QURE) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
uniQure (QURE) Surges 76.5%: Is This an Indication of Further Gains?
uniQure (QURE) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
07/09 13:48 EST - seekingalpha.com
uniQure: Positive HD AMT-130 Treatment Data Leads To Several Other Catalysts
uniQure reported positive interim results across phase 1/2 studies, using AMT-130 for the treatment of patients with Huntington's Disease, leading to an 80% slowing of disease progression. The company plans to meet with the FDA in H2 2024 to discuss the possible Accelerated Approval pathway of AMT-130 for the treatment of patients with Huntington's Disease. 36-month data from the phase 1/2 studies using AMT-130 for the treatment of patients with Huntington's Disease is expected in mid-2025.
uniQure: Positive HD AMT-130 Treatment Data Leads To Several Other Catalysts
uniQure reported positive interim results across phase 1/2 studies, using AMT-130 for the treatment of patients with Huntington's Disease, leading to an 80% slowing of disease progression. The company plans to meet with the FDA in H2 2024 to discuss the possible Accelerated Approval pathway of AMT-130 for the treatment of patients with Huntington's Disease. 36-month data from the phase 1/2 studies using AMT-130 for the treatment of patients with Huntington's Disease is expected in mid-2025.
07/09 10:35 EST - zacks.com
Down -29.74% in 4 Weeks, Here's Why You Should You Buy the Dip in uniQure (QURE)
uniQure (QURE) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Down -29.74% in 4 Weeks, Here's Why You Should You Buy the Dip in uniQure (QURE)
uniQure (QURE) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
07/09 10:27 EST - investorplace.com
Why Is uniQure (QURE) Stock Up 51% Today?
UniQure (NASDAQ: QURE ) stock is on the rise Tuesday after the company provided investors with interim clinical data from a PhaseI/II clinical trials for AMT-130. These clinical trials are evaluating the use of AMT-130 as a treatment for Huntington's Disease.
Why Is uniQure (QURE) Stock Up 51% Today?
UniQure (NASDAQ: QURE ) stock is on the rise Tuesday after the company provided investors with interim clinical data from a PhaseI/II clinical trials for AMT-130. These clinical trials are evaluating the use of AMT-130 as a treatment for Huntington's Disease.
07/09 07:05 EST - globenewswire.com
uniQure Announces Positive Interim Data Update Demonstrating Slowing of Disease Progression in Phase I/II Trials of AMT-130 for Huntington's Disease
~ Achieved statistically significant, dose-dependent, and durable evidence of potential therapeutic benefit; Patients receiving high-dose AMT-130 showed 80% slowing of disease progression in the composite Unified Huntington's Disease Rating Scale (cUHDRS) at 24 months compared to a propensity score-weighted external control ~
uniQure Announces Positive Interim Data Update Demonstrating Slowing of Disease Progression in Phase I/II Trials of AMT-130 for Huntington's Disease
~ Achieved statistically significant, dose-dependent, and durable evidence of potential therapeutic benefit; Patients receiving high-dose AMT-130 showed 80% slowing of disease progression in the composite Unified Huntington's Disease Rating Scale (cUHDRS) at 24 months compared to a propensity score-weighted external control ~
07/01 07:05 EST - globenewswire.com
uniQure Announces Sale of Commercial Manufacturing Facility to Genezen
~ Proposed divestiture streamlines uniQure's focus and represents an important milestone in its ongoing effort to significantly reduce operating expenses ~
uniQure Announces Sale of Commercial Manufacturing Facility to Genezen
~ Proposed divestiture streamlines uniQure's focus and represents an important milestone in its ongoing effort to significantly reduce operating expenses ~
07/01 07:05 EST - prnewswire.com
Genezen to Acquire uniQure's Commercial Gene Therapy Manufacturing Operations in Lexington, MA
Strategic acquisition will enable Genezen to deliver late-phase and commercial gene therapy development and manufacturing services to customers around the world. BOSTON and INDIANAPOLIS , July 1, 2024 /PRNewswire/ -- Genezen, a best-in-class gene therapy CDMO, today announced an agreement to acquire uniQure's (Nasdaq: QURE) commercial gene therapy operations in Lexington, MA, bringing a strategic manufacturing facility and a world-class team of employees to the company.
Genezen to Acquire uniQure's Commercial Gene Therapy Manufacturing Operations in Lexington, MA
Strategic acquisition will enable Genezen to deliver late-phase and commercial gene therapy development and manufacturing services to customers around the world. BOSTON and INDIANAPOLIS , July 1, 2024 /PRNewswire/ -- Genezen, a best-in-class gene therapy CDMO, today announced an agreement to acquire uniQure's (Nasdaq: QURE) commercial gene therapy operations in Lexington, MA, bringing a strategic manufacturing facility and a world-class team of employees to the company.
06/03 07:05 EST - globenewswire.com
uniQure Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Investigational Gene Therapy AMT-130 in Huntington's Disease
~ Designation based on 24-month interim Phase I/II clinical data for AMT-130 announced in December 2023 ~ ~ AMT-130 is the first therapeutic candidate to receive RMAT Designation for Huntington's disease ~ ~ Receiving RMAT designation enables increased collaboration with the FDA on regulatory approval planning, in addition to the opportunity for expedited product development ~ LEXINGTON, Mass. and AMSTERDAM, June 03, 2024 (GLOBE NEWSWIRE) -- uniQure N.V.
uniQure Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Investigational Gene Therapy AMT-130 in Huntington's Disease
~ Designation based on 24-month interim Phase I/II clinical data for AMT-130 announced in December 2023 ~ ~ AMT-130 is the first therapeutic candidate to receive RMAT Designation for Huntington's disease ~ ~ Receiving RMAT designation enables increased collaboration with the FDA on regulatory approval planning, in addition to the opportunity for expedited product development ~ LEXINGTON, Mass. and AMSTERDAM, June 03, 2024 (GLOBE NEWSWIRE) -- uniQure N.V.
05/07 07:05 EST - globenewswire.com
uniQure Announces First Quarter 2024 Financial Results and Highlights Recent Company Progress
~ On track to initiate FDA interaction regarding AMT-130 in second quarter of 2024 and provide a clinical update from the Phase I/II trials in mid-2024 ~ ~ Clinical trial initiation for Fabry disease on track to begin in second quarter of 2024, followed by refractory mesial temporal lobe epilepsy and SOD1-ALS in third quarter of 2024 ~ ~ Comprehensive review of operations and options to reduce expenses underway and expected to be completed in mid-2024 ~ LEXINGTON, Mass. and AMSTERDAM, May 07, 2024 (GLOBE NEWSWIRE) -- uniQure N.V.
uniQure Announces First Quarter 2024 Financial Results and Highlights Recent Company Progress
~ On track to initiate FDA interaction regarding AMT-130 in second quarter of 2024 and provide a clinical update from the Phase I/II trials in mid-2024 ~ ~ Clinical trial initiation for Fabry disease on track to begin in second quarter of 2024, followed by refractory mesial temporal lobe epilepsy and SOD1-ALS in third quarter of 2024 ~ ~ Comprehensive review of operations and options to reduce expenses underway and expected to be completed in mid-2024 ~ LEXINGTON, Mass. and AMSTERDAM, May 07, 2024 (GLOBE NEWSWIRE) -- uniQure N.V.
02/28 09:20 EST - zacks.com
UniQure (QURE) Reports Q4 Loss, Tops Revenue Estimates
UniQure (QURE) came out with a quarterly loss of $1.53 per share versus the Zacks Consensus Estimate of a loss of $1.54. This compares to earnings of $0.15 per share a year ago.
UniQure (QURE) Reports Q4 Loss, Tops Revenue Estimates
UniQure (QURE) came out with a quarterly loss of $1.53 per share versus the Zacks Consensus Estimate of a loss of $1.54. This compares to earnings of $0.15 per share a year ago.
02/28 07:05 EST - globenewswire.com
uniQure Announces 2023 Financial Results and Highlights Recent Company Progress
~ Presented promising clinical update from U.S. and European Phase I/II trials of AMT-130 in Huntington's disease; Up to three years of follow-up data to be presented in mid-2024; Regulatory interactions and clarity on potential strategies for clinical development expected in 2024 ~
uniQure Announces 2023 Financial Results and Highlights Recent Company Progress
~ Presented promising clinical update from U.S. and European Phase I/II trials of AMT-130 in Huntington's disease; Up to three years of follow-up data to be presented in mid-2024; Regulatory interactions and clarity on potential strategies for clinical development expected in 2024 ~